Statement Of Cash Flows [Abstract]

Transgene - Filing #858281

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
20 303 EUR
25 909 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
20 272 EUR
5 789 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
- EUR
34 129 EUR
Payments of lease liabilities, classified as financing activities
1 281 EUR
1 277 EUR
Proceeds from government grants, classified as financing activities
455,000 EUR
603,000 EUR
Cash flows from (used in) financing activities
1 477 EUR
32 320 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
- EUR
12,000 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
1 508 EUR
634,000 EUR
Cash and cash equivalents
4 403 EUR
5 911 EUR
5 277 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.